S&P Futures
5,884.50 -11.75 (-0.20%) Dow Futures
43,110.00 -67.00 (-0.16%) Nasdaq Futures
20,461.25 -58.25 (-0.28%) Russell 2000 Futures
2,248.60 -6.90 (-0.31%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,747.80 +8.90 (+0.32%)
Processa Pharmaceuticals, Inc. (PCSA)
After hours:
| Previous Close | 1.3600 |
| Open | 1.4100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.3634 - 1.4200 |
| 52 Week Range | 1.1900 - 17.4000 |
| Volume | |
| Avg. Volume | 1,019,870 |
| Market Cap | 4.592M |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.2500 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
GlobeNewswireProcessa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to define the optimal dosage regimen in patients with metastatic breast cancer HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs wit
- GlobeNewswire
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September: H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, at the Lotte New York Palace Hotel. Management will be holding one-on-one meetings with investors and will deliver a company presentation. The recorded presentation will be available on demand be
- GlobeNewswire
Processa Pharmaceuticals Provides Product Pipeline and Financial Update
Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde® HANOVER, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherap
